Turing Pharmaceuticals infectious news

Turing CEO Martin Shkreli said in an interview the company will commit to a “modest” price reduction of about 10% for toxoplasmosis drug Daraprim pyrimethamine by year end. Shkreli also said he is considering discounts on the order of 25-50% for smaller hospitals that cannot afford to stock the dihydrofolate reductase (DHFR) inhibitor. The company said further discussions on Daraprim discounts are “premature.” ...